KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
PLoS Medicine - United States
doi 10.1371/journal.pmed.0020017
Full Text
Open PDFAbstract
Available in full text
Date
January 25, 2005
Authors
Publisher
Public Library of Science (PLoS)